# Myofascial Pain Syndrome

## Introduction

Myofascial pain syndrome (MPS) is one of the most common causes of chronic musculoskeletal pain. It is characterized by the presence of myofascial trigger points — hyperirritable nodules within taut bands of skeletal muscle that produce local and referred pain patterns. MPS affects an estimated 30-85% of patients presenting to pain clinics, yet it remains frequently underdiagnosed due to the absence of confirmatory laboratory or imaging biomarkers and reliance on clinical examination skills.

## Trigger Point Mechanisms

### Peripheral Mechanisms

The prevailing model for trigger point formation is the integrated hypothesis proposed by Simons. It proposes that trigger points arise from dysfunctional motor endplates with excessive acetylcholine release, which leads to sustained sarcomere contraction, local ischemia, and release of sensitizing substances including bradykinin, substance P, CGRP, serotonin, and prostaglandins. The energy crisis model builds on this: sustained contraction compresses local capillaries, creating a hypoxic, acidic microenvironment that perpetuates the contracture cycle. Palpable taut bands represent groups of sarcomeres in maximal contraction, while adjacent sarcomeres are stretched, creating the characteristic nodular texture. Needle EMG studies at trigger point sites demonstrate continuous low-amplitude spontaneous electrical activity consistent with dysfunctional endplate noise, providing objective evidence for the hypothesis.

### Central Mechanisms

Persistent nociceptive input from active trigger points drives dorsal horn neuroplasticity, resulting in central sensitization with expanded receptive fields, allodynia, and hyperalgesia. The characteristic referred pain patterns of myofascial trigger points are mediated by convergence of afferent input at the dorsal horn and activation of latent referred pain zones. Impaired descending inhibitory control contributes to the transition from acute to chronic MPS. When MPS becomes longstanding, it may evolve into a widespread pain syndrome with features overlapping fibromyalgia, driven by progressive central sensitization.

<image>Detailed medical illustration showing the integrated hypothesis of myofascial trigger point formation, depicting a cross-section of skeletal muscle with a normal motor endplate compared to a dysfunctional endplate showing excessive acetylcholine release, sustained sarcomere contraction forming a contraction knot, compressed capillaries causing local ischemia, and release of inflammatory mediators in the surrounding tissue, with all components clearly labeled</image>

## Diagnostic Criteria

Diagnosis of MPS is clinical and based on the findings described by Simons, Travell, and Simons.

### Essential Criteria

Three findings are essential: a palpable taut band in skeletal muscle, a tender spot (trigger point) within that taut band, and reproduction of the patient's recognized pain pattern with sustained pressure or needling — this last criterion distinguishes an active trigger point from a latent one.

### Confirmatory Features

Several additional features support the diagnosis. The local twitch response is a brief, visible, or palpable contraction of the taut band elicited by snapping palpation or needle insertion. Referred pain — predictable pain referral to a distant site characteristic of the involved muscle — is another hallmark. Restricted range of motion results from pain and taut band shortening. The jump sign is an exaggerated withdrawal response to palpation of the trigger point.

### Active vs. Latent Trigger Points

Active trigger points are spontaneously painful and reproduce the patient's clinical pain complaint. Latent trigger points are not spontaneously painful but may restrict range of motion and cause weakness, and they can be activated by physical or psychological stressors.

## Dry Needling vs. Wet Needling

| Feature | Dry Needling | Wet Needling (TPI with Local Anesthetic) | Botulinum Toxin Injection |
|---------|-------------|----------------------------------------|--------------------------|
| Needle type | Solid filament (25-32 gauge acupuncture) | Hypodermic (25-27 gauge) | Hypodermic |
| Injectate | None | Lidocaine 1% or bupivacaine 0.25% | OnabotulinumtoxinA 10-50 U/point |
| Primary mechanism | Mechanical disruption of endplate | Mechanical disruption + anesthetic | ACh release inhibition at NMJ |
| Onset of relief | Immediate (post-soreness 24-48 hr) | Immediate | Delayed (3-7 days) |
| Duration of effect | Days to weeks | Days to weeks | 3-4 months |
| Evidence quality | Moderate (superior to sham) | Strong (short-term pain reduction) | Mixed/insufficient (Cochrane 2014) |
| Cost | Low | Low | High |
| Practitioner | Physical therapists (varies by state) | Physicians, advanced practice providers | Physicians |
| Repeat frequency | Can repeat frequently | Can repeat frequently | Every 3-4 months minimum |

### Dry Needling

Dry needling involves inserting a solid filament needle (typically an acupuncture needle, 25-32 gauge) directly into the trigger point to elicit a local twitch response, which is considered a key therapeutic indicator. The mechanism involves mechanical disruption of dysfunctional endplates, reduction in spontaneous electrical activity, washout of sensitizing substances, and elicitation of a local stretch reflex. Moderate-quality evidence supports short-term improvements in pain and function, with systematic reviews suggesting superiority over sham needling. Obtaining a local twitch response is associated with better outcomes. The advantages of dry needling include no injection risk (no medication-related adverse effects), the ability to repeat it frequently, and its widespread practice by physical therapists in many jurisdictions.

### Wet Needling (Trigger Point Injections)

Trigger point injections involve injecting a substance into the trigger point using a 25-27 gauge hypodermic needle, with multiple passes (fanning technique) to elicit local twitch responses. The most commonly used injectate is local anesthetic (lidocaine 1% or bupivacaine 0.25%), which provides immediate pain relief and allows post-injection stretching. Normal saline has shown equivalent efficacy to local anesthetic in some studies, suggesting that the mechanical effect of the needle is the primary therapeutic mechanism. Corticosteroid injection has no proven benefit over local anesthetic alone and is not recommended for routine trigger point injection. Strong evidence demonstrates that trigger point injection with local anesthetic reduces pain in the short term, and the work of Hong (1994) was pivotal in showing that mechanical disruption of the trigger point appears more important than the specific injectate used.

<image>Step-by-step illustration of trigger point injection technique demonstrating pincer or flat palpation of the taut band, needle insertion at the trigger point with fanning technique showing multiple needle redirections to elicit local twitch responses, and the characteristic referred pain pattern from an upper trapezius trigger point referring to the temporal region, with labeled anatomical landmarks and needle angles</image>

## Botulinum Toxin Evidence

Botulinum toxin inhibits acetylcholine release at the neuromuscular junction, which theoretically addresses the underlying endplate dysfunction proposed in the integrated hypothesis. Type A (onabotulinumtoxinA) is the most studied formulation, with typical doses of 10-50 units per trigger point. However, the evidence is mixed and largely disappointing — a 2012 Cochrane review found insufficient evidence to support botulinum toxin for MPS, and subsequent RCTs have shown variable results. It may have a niche role in refractory cases where repeated trigger point injections and dry needling provide only transient relief, particularly in the upper trapezius, cervical paraspinals, and piriformis. Limitations include high cost, delayed onset (3-7 days), potential for focal weakness, and the need for repeated injections every 3-4 months. The current consensus is that botulinum toxin is not recommended as first-line treatment for MPS and should be reserved for carefully selected refractory cases.

## Integrated Physical Therapy Approaches

Successful MPS management requires a multimodal strategy addressing both the trigger points themselves and the perpetuating factors that sustain them. Stretch and spray involves applying a vapocoolant spray (ethyl chloride or fluoromethane) over the muscle in the direction of referred pain, followed by passive stretching through full range of motion. Manual therapy techniques include ischemic compression (sustained pressure), myofascial release, and strain-counterstrain approaches. Postural correction requires identification and correction of biomechanical perpetuating factors such as leg length discrepancy, forward head posture, scoliosis, and ergonomic deficiencies. A progressive therapeutic exercise program incorporating strengthening, stretching, and eccentric loading for coexisting chronic tendinopathies is essential. Modalities such as TENS, ultrasound, and laser therapy have limited evidence but may serve as useful adjuncts. Perhaps most importantly, perpetuating factors must be addressed — nutritional deficiencies (vitamin D, iron, B12), sleep disorders, psychological stressors, and hormonal imbalances can all sustain chronic MPS, and without correcting them, trigger points will recur despite effective direct treatment.

<image>Anatomical chart showing common myofascial trigger point locations and their characteristic referred pain patterns for the upper trapezius (referring to temporal region), levator scapulae (referring to neck and medial scapular border), infraspinatus (referring to anterior shoulder and arm), and quadratus lumborum (referring to hip and lateral thigh), with red X marks at trigger point locations and shaded referred pain zones</image>

## Clinical Pearls

The local twitch response during needling is the single best indicator of successful trigger point deactivation and correlates with improved outcomes. The choice of injectate — local anesthetic, saline, or dry needling — is less important than the mechanical disruption of the trigger point, a finding demonstrated in multiple comparative studies. Perpetuating factors (postural, nutritional, psychological, sleep-related) must always be identified and addressed, because without doing so, trigger points will recur despite effective treatment. MPS and fibromyalgia exist on a continuum of central sensitization, and patients with widespread MPS should be screened for fibromyalgia criteria. Post-injection soreness lasting 24-48 hours is expected, and patients should be instructed to apply moist heat and perform gentle stretching during this period.

## References

1. Simons DG, Travell JG, Simons LS. *Travell & Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual*. 2nd ed. Baltimore: Williams & Wilkins; 1999.
2. Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point: the importance of the local twitch response. *Am J Phys Med Rehabil*. 1994;73(4):256-263.
3. Cagnie B, Castelein B, Pollie F, Steelant L, Verhoeyen H, Cools A. Evidence for the use of ischemic compression and dry needling in the management of trigger points of the upper trapezius in patients with neck pain: a systematic review. *Am J Phys Med Rehabil*. 2015;94(7):573-583.
4. Soares A, Andriolo RB, Atallah AN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. *Cochrane Database Syst Rev*. 2014;(7):CD007533.